-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Analysis
| Brand | Therapeutic category |
|---|---|
|
Arixtra |
Antithrombotic agent |
|
Diprivan |
General anaesthetic |
|
Fraxiparine |
Low molecular weight heparin |
|
Naropin |
Regional anaesthetic |
|
Ultiva |
Injectable general anaesthetic |
0
Products
Launched
Launched
(2021: 3)
Product
Recalls
Recalls
(2021: Nil)
10
%
Average Staff
Turnover
Turnover
(2021: 14%)
Work-related
Facilities
Facilities
(2021: Nil)
435
Sales
Representatives
Representatives
(2021: 574)
900
Permanent
Employees
Employees
(June 2021: 1,214)
| Revenue |
2022 R’million |
2021 (CER) R’million |
Change % |
|---|---|---|---|
|
Total Commercial Pharmaceuticals |
5 117 |
5 127 |
0 |
|
Regional Brands |
613 |
614 |
0 |
|
Sterile Focus Brands |
4 503 |
4 513 |
0 |
|
Manufacturing – API Chemicals |
112 |
75 |
49 |
|
Total |
5 228 |
5 202 |
0 |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 75
- Asia 25
Revenue by segment (%)
- Sterile Focus Brands 86
- Regional Brands 12
- Manufacturing - API Chemicals 2
- China’s pharmaceutical market including hospital and retail channels is expected to grow at 2,4% CAGR (2021 to 2026). The market is expected to be valued at RMB1,234 billion by 2026.
- The Korea total pharmaceutical market grew 8,2% MAT Q1 2022 versus Q1 MAT 2021.
Source: IQVIA Market Prognosis 2022M03 & IQVIA MAT 2022
Q1 Vs MAT 2021 Q1
MAT = Moving annual total.
